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The Hippo pathway regulates organ size by controlling both
cell proliferation and apoptosis. TAZ functions as a transcrip-
tional co-activator downstream of the Hippo pathway and has
been implicated in human cancer development. A key step in
the Hippo-TAZ pathway is phosphorylation of TAZ by LATS
kinase, which leads to TAZ inhibition by both cytoplasmic re-
tention and degradation. However, the mechanism of TAZ
dephosphorylation and the responsible phosphatase are un-
known. Here, we identified PP1 as a bona fide TAZ phospha-
tase. PP1A dephosphorylates TAZ at Ser-89 and Ser-311, pro-
motes TAZ nuclear translocation, and stabilizes TAZ by
disrupting the binding to the SCF E3 ubiquitin ligase. Further-
more, ASPP2 facilitates the interaction between TAZ and PP1
to promote TAZ dephosphorylation. As a result, PP1 and
ASPP2 increase TAZ-dependent gene expression. This study
demonstrates that PP1A and ASPP2 play a critical role in pro-
moting TAZ function by antagonizing the LATS kinase
through TAZ dephosphorylation.
Genetic screens in Drosophila have delineated a new tumor
suppressor pathway, the Hippo pathway, which regulates or-
gan size by controlling both cell proliferation and apoptosis
(1). Both the components and functions of the Hippo pathway
are conserved from Drosophila to mammals. In mammalian
cells, LATS1/2 and MST1/2 are the homologs of Drosophila
Warts and Hippo, respectively (2). YAP, the mammalian or-
tholog of Drosophila Yorkie, has been demonstrated to be
phosphorylated and inhibited by LATS (3, 4). TAZ, first iden-
tified as a 14-3-3-binding protein, shares 50% sequence
identity with YAP and has also been shown to function as a
transcriptional co-activator downstream of the Hippo path-
way (5, 6). TAZ is involved in the development of multiple
organs such as the lung, fat, muscle, bone, limb, and heart, as
well as in many cellular, processes including stem cell differ-
entiation, cell proliferation, and epithelial-mesenchymal tran-
sition (6–12). Taz knockout mice develop two severe abnor-
malities: polycystic kidney disease and emphysema (13, 14).
Notably, elevated TAZ expression is observed in 20% of
breast cancers, especially invasive ductal carcinomas (12).
We previously showed that the activity of TAZ is inhibited
by LATS kinase in a mechanism similar to YAP regulation by
the Hippo pathway (6). There are four HXRXXS LATS phos-
phorylation motifs in TAZ. We have demonstrated that phos-
phorylation of TAZ at Ser-89 by LATS promotes its interac-
tion with 14-3-3, resulting in cytoplasmic sequestration and
functional inhibition of TAZ. The S89A mutation makes TAZ
partially resistant to inhibition by the Hippo pathway (6). In
addition, TAZ stability is also regulated by LATS phosphory-
lation. A dual phosphorylation of TAZ by LATS and CK1
creates a binding site for -TrCP (beta-Transducin repeat
containing protein), the substrate-recruiting subunit of the
SCF-TrCP E3 ubiquitin ligase (15). Phosphorylation of TAZ at
Ser-311 by LATS provides the priming site for subsequent
CK1 phosphorylation at Ser-314 in TAZ, therefore creating a
functional phosphodegron for -TrCP binding (15). There-
fore, phosphorylation plays a major role in TAZ regulation in
both subcellular localization and protein levels.
Protein phosphorylation is highly dynamic and reversible.
This raises questions about whether and which protein phos-
phatases are involved in TAZ regulation. Ser/Thr protein
phosphatases are classified into three families: PPM (metal-
dependent protein phosphatases), PPP (phosphoprotein phos-
phatases), and FCP/SCP (TFIIF-associating component of
RNA polymerase II CTD phosphatase/small) (16, 17). The
PPP superfamily members, including PP1, PP2A (PP2), PP2B
(PP3), and PP4–7, share the same catalytic mechanism (18).
PP1 is a major eukaryotic Ser/Thr protein phosphatase in-
volved in various cellular processes (19). Interestingly, in our
previous TAZ affinity purification to identify TAZ-binding
proteins (20), we also identified PP1A (a catalytic subunit of
PP1) in the TAZ complex, indicating that PP1A is potentially
TAZ phosphatase. Notably, PP1A has been reported to inter-
act with ASPP2 (21), which is a member of the ASPP (ankyrin
repeat-containing, SH3 domain-containing, and proline-rich
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region-containing protein) family, containing four ankyrin
repeats, an SH3 domain, and a proline-rich region (22–24).
Through C-terminal ankyrin repeats and the SH3 domain,
ASPP2 has been shown to interact with numerous proteins,
including p53 (25), Bcl-2 (26), RelA p65 (27), APC-2 (APCL)
(28), YAP (29), and APP-BP1 (30). YAP, the mammalian hom-
olog of TAZ, interacts with ASPP2 through the WW domain-
and SH3 domain-binding motifs, but the biochemical and
biological significance underlying the YAP-ASPP2 interaction
is largely unknown.
In this stidy, we show that PP1A dephosphorylates TAZ at
Ser-89 and Ser-311. By doing so, PP1A increases TAZ nuclear
localization and protein levels.We also observed that ASPP2
facilitates the interaction between TAZ and PP1A, thus leading
to TAZ dephosphorylation and induction of TAZ target gene
expression. Our study identifies PP1A as a TAZ phosphatase and
the function of ASPP2 and PP1A in TAZ regulation.
EXPERIMENTAL PROCEDURES
Cell Culture and Transfection—HEK293T cells and HeLa
cells were cultured in DMEM (Invitrogen) supplemented with
10% FCS (HyClone), 100 units/ml penicillin, and streptomy-
cin (Invitrogen). MCF10A cells were maintained in DMEM/
F-12 medium (Invitrogen) supplemented with 5% horse se-
rum (Invitrogen), 20 ng/ml EGF, 0.5 g/ml hydrocortisone,
10 g/ml insulin, 100 ng/ml cholera toxin, 100 units/ml peni-
cillin, and streptomycin (Invitrogen). Cell transfection was
performed using Lipofectamine 2000 (Invitrogen) or the cal-
cium phosphate method. Cells were harvested at 24 h post-
transfection for protein analyses.
To establish stable TAZ-expressing and PP1-expressing
cells, pBABE-TAZ and pQCXIH-PP1 retroviruses were gen-
erated and used to infect MCF10A cells, and stable pools were
selected in puromycin (1 g/ml) and hygromycin (200 g/
ml), respectively.
Western Blot Analysis and Immunoprecipitation—Protein
lysates were prepared by lysing 293T cells in buffer containing
50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.1% SDS, 0.5% de-
oxycholate, 1% Nonidet P-40, 1 mM EDTA, 1 mM PMSF, 25
mM NaF, and mixture protease inhibitors (Roche Applied Sci-
ence). Cell lysate (40 g) was resolved by SDS-PAGE, fol-
lowed by Western blot analysis. Antibodies of FLAG (A00170,
GenScript; or A2220, Sigma), HA (F7; sc7392, Santa Cruz Bio-
technology), His (THETM His tag antibody, GenScript),
ASPP2 (611354, BD Biosciences), lamins A and C (A01455,
GenScript), -tubulin (RB-9281-P0, Lab Vision Corp.), and
-actin (13E5; 4970, Cell Signaling) were purchased commer-
cially. Anti-phospho-Ser-311 and anti-phospho-Ser-89 TAZ
antibodies were raised in rabbits using synthetic phosphopep-
tide as an antigen.
For immunoprecipitation experiments, 1 mg of cell lysate was
incubated with anti-FLAGM2-agarose for 3 h at 4 °C. Beads
were washed three times with lysis buffer and centrifuged at
5000  g for 5 min between each wash. Protein was eluted from
beads with 50 l of Laemmli sample buffer (Bio-Rad). Lysates
were resolved on 8 or 10% SDS-polyacrylamide gels and trans-
ferred onto nitrocellulose (Bio-Rad) forWestern blotting.
Phosphatase Assay—PP1 (P0754S) was purchased from
New England Biolabs. 293T cells were cotransfected with
FLAG-TAZ and HA-LATS2. After 24 h of incubation, 293T
cells were lysed with lysis buffer, and the cell lysate was incu-
bated with anti-FLAGM2-agarose for 3 h at 4 °C. Beads were
washed three times, first with lysis buffer and then with 1
NEBuffer for pyridoxamine phosphate supplemented with
MnCl2. FLAG-TAZ was eluted by 3FLAG peptide in 1
NEBuffer for pyridoxamine phosphate supplemented with
MnCl2. The elution was divided equally, and an indicated
amount of PP1 was added. After incubation for 30 min at
30 °C, the eluted lysates were added to SDS loading buffer and
boiled at 99 °C. The phosphorylation level of FLAG-TAZ was
determined by Western blotting.
Subcellular Fractionation—293T cells were washed with
PBS and transferred to a 1.5-ml tube. The cells were lysed
with Harvest buffer (10 mM HEPES (pH 7.9), 50 mM NaCl,
0.5 M sucrose, 0.1 mM EDTA, 0.5% Triton X-100, 1 mM DTT,
1 mM PMSF, 25 mM NaF, and mixture protease inhibitors).
After incubation for 5 min on ice, the lysate was centri-
fuged at 1000 rpm for 10 min. The pellet (nuclear fraction)
was washed three times with wash buffer (10 mM HEPES
(pH 7.9), 10 mM KCl, 0.1 mM EDTA, and 0.1 mM EGTA)
and then resuspended with 1 SDS loading buffer. The
supernatant (cytoplasmic fraction) was transferred to a
new tube and centrifuged at 14,000 rpm for another 15
min. The supernatant was transferred to a new tube and
boiled in 1 SDS loading buffer.
RNA Isolation and Real-time PCR—Total RNA was isolated
from cultured cells using TRIzol reagent (Invitrogen). cDNA
was synthesized by reverse transcription using oligo(dT) as
the primer, followed by real-time PCR with gene-specific
primers in the presence of SYBR Premix Ex Taq (DRR041A,
TaKaRa). The relative abundance of mRNA was calculated by
normalization to GAPDH mRNA.
RESULTS
PP1A Is a TAZ Phosphatase—As a transcription co-activa-
tor, TAZ must interact with a downstream transcription fac-
tor to induce gene expression. In our previous work, we per-
formed TAZ affinity purification to identify TAZ target
transcription factors (20). Interestingly, this purification strat-
egy identified multiple putative TAZ-interacting proteins,
which included not only all four TEAD (TEA domain) family
members but also PP1A. In fact, multiple peptides for the
PP1A protein were identified (Fig. 1A). These peptides were
absent from control purification of cells infected with the
streptavidin-binding peptide vector. To confirm the interaction
between TAZ and PP1A, we performed co-immunoprecipitation
experiments and found that HA-PP1A could be readily pulled
down by TAZ (Fig. 1B, left panel). Similarly, reciprocal co-immu-
noprecipitation experiments also showed that TAZwas co-pre-
cipitated with PP1A (Fig. 1B, right panel).
We recently characterized the conserved HXRXXS motifs
in YAP and TAZ (3, 6). Both YAP and TAZ are phosphory-
lated by LATS kinase (3,6). However, the phosphatase respon-
sible for dephosphorylation of both YAP and TAZ is un-
known. The identification of PP1A in the TAZ purification
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led us to test whether PP1A is a phosphatase for TAZ. To this
end, we examined the effect of PP1A on TAZ phosphoryla-
tion at Ser-89. As shown in Fig. 1C, ectopic expression of
LATS dramatically induced TAZ phosphorylation at Ser-89,
but coexpression of PP1A significantly decreased TAZ phos-
phorylation at Ser-89 in a dose-dependent manner. PP1A be-
longs to the PPP family, which includes PP1 and PP2A. Re-
cently, a PP2A complex has been reported to function as a
negative regulator of the Hippo pathway in Drosophila (31).
To identify whether the above observed dephosphorylation of
TAZ is unique to PP1A, we also examined the effect of PP2A on
TAZ phosphorylation at Ser-89. Interestingly, overexpression of
onlyWT PP1A, but not the phosphatase-inactive mutant H248K
or PP2A, dramatically decreased TAZ phosphorylation at Ser-89
(Fig. 1D). Furthermore, we performed an in vitro dephosphoryl-
ation assay and found that TAZ phosphorylation at Ser-89 was
decreased with increasing amounts of PP1 (Fig. 1E). PP1A is in-
hibited by okadaic acid with an IC50 of 20 nM, whereas PP2A is
muchmore sensitive to okadaic acid, with an IC50 of 0.2 nM (32).
Calyculin A is a more efficient inhibitor for both PP1A and PP2A
(33). Indeed, both okadaic acid and calyculin A significantly in-
creased TAZ phosphorylation at Ser-89 and resulted in an obvi-
ous TAZmobility shift as detected by the anti-TAZ antibody,
indicating that endogenous TAZ is dynamically regulated by
reversible phosphorylation (Fig. 1F and supplemental Fig. 1). The
concentrations of okadaic acid and calyculin A needed to in-
crease TAZ phosphorylation were consistent with PP1A as a
physiological TAZ phosphatase.
PP1A Stabilizes TAZ by Decreasing the Interaction between
TAZ and -TrCP—Our recent work has shown that LATS
and CK1 phosphorylate TAZ and promote TAZ interaction
with the SCF E3 ubiquitin ligase and degradation (15). If
PP1A dephosphorylates TAZ, it should stabilize TAZ by an-
tagonizing the effect of LATS. To this end, we examined the
effect of okadaic acid on TAZ protein levels. As shown in Fig.
2A, okadaic acid treatment resulted in a visible decrease in the
TAZ protein level and increased TAZ phosphorylation.
MG132 treatment blocked the effect of okadaic acid on TAZ
protein levels, indicating that PP1A increases TAZ protein
levels by suppressing proteasome-mediated degradation. To
further characterize the PP1A effect on TAZ stability, we gener-
ated PP1A stable pools using a retrovirus.We observed an obvi-
ous increase in TAZ protein in pBABA-FLAG-TAZ/MCF10A
cells stably expressing PP1A (Fig. 2B). Furthermore, the half-life
of TAZ in the PP1A-expressing cells was significantly increased
compared with that in the vector control cells (Fig. 2C).
FIGURE 1. PP1A dephosphorylates TAZ. A, mass spectrometry identification of PP1A in FLAG-TAZ immunoprecipitation. Cell lysate from 293T cells stably
expressing FLAG-TAZ was immunoprecipitated with streptavidin-binding peptide beads, followed by washing four times and trypsin digestion for further
mass spectrometry analysis. The protein sequences of PP1A peptides identified by mass spectrometry are shown. B, TAZ binds to PP1A. HA-PP1A/FLAG-
PP1A was cotransfected with FLAG-TAZ/GFP-TAZ into HEK293T cells as indicated. PP1A and TAZ associations were examined by reciprocal co-immunopre-
cipitation as indicated. C, PP1A dephosphorylates TAZ at Ser-89. The indicated plasmids were coexpressed in 293T cells, and TAZ phosphorylation at Ser-89
was determined by Western blotting. D, PP1 (but not PP2A) dephosphorylates TAZ at Ser-89. The indicated plasmids were coexpressed in 293T cells, and
TAZ phosphorylation at Ser-89 was determined by Western blotting. H248K denotes the phosphatase-inactive mutant. E, PP1A dephosphorylates TAZ at
Ser-89 in vitro. FLAG-TAZ was immunoprecipitated from transfected 293T cells and then incubated with the indicated amount of recombinant PP1. Phos-
phorylation of TAZ was detected by anti-phospho-Ser-89 TAZ antibody. F, phosphatase inhibitors induce TAZ phosphorylation at Ser-89. 293T cells were
treated with phosphatase inhibitors as indicated, and TAZ phosphorylation at Ser-89 was determined by Western blotting. OA, okadaic acid; CA, calyculin A.
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Our recent study identified -TrCP as a TAZ-binding pro-
tein to recruit the SCF E3 ubiquitin ligase (15). We then de-
termined the effect of PP1A on the interaction between TAZ
and -TrCP. PP1A overexpression decreased the interaction
between TAZ and -TrCP in both the absence and presence
of LATS coexpression (Fig. 2D). Furthermore, okadaic acid
treatment increased TAZ phosphorylation and its interaction
with -TrCP (Fig. 2E). TAZ phosphorylation at Ser-311 is
required for C-terminal phosphodegron-mediated degra-
dation (15). We then determined the effect of PP1A on
TAZ phosphorylation at Ser-311. We observed a dramati-
cally decreased TAZ phosphorylation at Ser-311 in the
presence of PP1A (Fig. 2F). As expected, PP1A efficiently
dephosphorylated TAZ at Ser-311 in vitro (Fig. 2G). Con-
FIGURE 2. PP1A stabilizes TAZ by decreasing the interaction between TAZ and -TrCP. A, phosphatase inhibitors promote proteasome-dependent TAZ
degradation. 293T cells stably expressing TAZ were treated with okadaic acid (OA) and MG132 as indicated. The steady-state level of TAZ was determined
by Western blotting. B, PP1A increases TAZ protein levels. Cell lysates from pBABE-FLAG-TAZ/MCF10A cells expressing the vector (Vec) or PP1A were sepa-
rated and probed with the indicated antibodies. C, PP1A stabilizes TAZ. pBABE-FLAG-TAZ/MCF10A cells expressing the vector or PP1A were treated with
cycloheximide (CHX; 20 g/ml) for the indicated times. TAZ protein levels were determined by Western blotting. D, PP1A decreases the interaction between
TAZ and -TrCP. The indicated plasmids were cotransfected into 293T cells. FLAG--TrCP was immunoprecipitated with anti-FLAG antibody, and the co-
precipitated GFP-TAZ was detected by TAZ Western blotting. E, okadaic acid treatment increases the interaction between TAZ and -TrCP. The indicated
plasmids were cotransfected into 293T cells. FLAG-TAZ was immunoprecipitated with anti-FLAG antibody, and the co-precipitated -TrCP was detected by
HA Western blotting. F, PP1A decreases TAZ phosphorylation at Ser-311. PP1A was coexpressed with TAZ in 293T cells, and TAZ phosphorylation at Ser-311
was determined by Western blotting. G, PP1A dephosphorylates TAZ at Ser-311 in vitro. FLAG-TAZ was immunoprecipitated from transfected 293T cells,
followed by incubation with the indicated amount of recombinant PP1. Phosphorylation of TAZ was detected by anti-phospho-Ser-311 TAZ antibody.
H, phosphatase inhibitors induce TAZ phosphorylation at Ser-311. 293T cells were treated with phosphatase inhibitors as indicated, and TAZ phosphoryla-
tion at Ser-311 was determined by Western blotting. CA, calyculin A.
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sistently, both okadaic acid and calyculin A significantly
increased TAZ phosphorylation at Ser-311 (Fig. 2H). These
results demonstrate that PP1A stabilizes TAZ by dephos-
phorylating TAZ at Ser-311 and decreasing its interaction
with -TrCP.
ASPP2 Increases the Interaction between TAZ and PP1A to
Promote TAZ Dephosphorylation—ASPP2 has been reported
to interact with multiple proteins, including PP1 (21–24). It
has also been reported to interact with the TAZ paralog YAP
(29). Indeed, ASPP2 was identified as a TAZ-interacting pro-
tein with a high score in our TAZ-streptavidin-binding pep-
tide tandem mass spectrometry experiment (supplemental
Fig. 2). Therefore, we speculated whether ASPP2 may facili-
tate the interaction between TAZ and PP1. To explore the
functional role of ASPP2 in TAZ dephosphorylation via PP1,
we first tested whether TAZ and PP1A can interact with
ASPP2. Both TAZ and PP1A could readily pull down ASPP2
(Fig. 3A). We also found that ASPP2 increased the interaction
between TAZ and PP1A (Fig. 3B). Furthermore, the TAZ
WWmutant abolished its interaction with ASPP2 (Fig. 3C),
FIGURE 3. ASPP2 increases the interaction between TAZ and PP1A. A, both TAZ and PP1A interact with ASPP2. ASPP2 plasmids were cotransfected into
293T cells as indicated. FLAG-TAZ or FLAG-PP1A was immunoprecipitated (IP) with anti-FLAG antibody, and the co-precipitated ASPP2-His was detected by
His Western blotting. B, ASPP2 facilitates the interaction between TAZ and PP1A. The indicated plasmids were cotransfected into 293T cells. FLAG-PP1A was
immunoprecipitated with anti-FLAG antibody, and the co-precipitated HA-TAZ or ASPP2-His was detected by HA or His Western blotting. C, TAZ requires its
WW domain to interact with ASPP2. The indicated plasmids were cotransfected into 293T cells. FLAG-TAZ was immunoprecipitated with anti-FLAG anti-
body, and the co-precipitated ASPP2-His was detected by His Western blotting. D, the WW domain in TAZ is required for ASPP2 to enhance the interaction
between TAZ and PP1A. The indicated plasmids were cotransfected into 293T cells. FLAG-TAZ was immunoprecipitated with anti-FLAG antibody, and the
co-precipitated ASPP2-His or HA-PP1A was detected by His or HA Western blotting. E, the WW domain in TAZ is important for its dephosphorylation by
ASPP2. The indicated plasmids were coexpressed in 293T cells, and TAZ phosphorylation at Ser-89 was determined by Western blotting. F, the PP1-binding
motif RVXF in ASPP2 is required for it to promote dephosphorylation of TAZ Ser-89. The indicated plasmids were coexpressed in 293T cells, and TAZ phos-
phorylation at Ser-89 was determined by Western blotting. G, ASPP2 knockdown increases TAZ phosphorylation at Ser-89. Three ASPP2 RNA interference
oligonucleotides were individually or in combination transfected into A375 cells as indicated. Levels of ASPP2 and TAZ phosphorylation at Ser-89 were de-
termined by Western blotting.
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similar to a previous report that YAP interacts with ASPP2 via
its WW1 domain (29). In addition, ASPP2 increased the inter-
action between WT TAZ and PP1A but had no promoting
effect on TAZWWmutant interaction with PP1A (Fig. 3D).
Moreover, ASPP2 overexpression dramatically decreased WT
TAZ phosphorylation at Ser-89 but had less of an effect on
TAZWWmutants (Fig. 3E and supplemental Fig. 3). The
above results suggest that ASPP2 may stimulate TAZ dephos-
phorylation partly by promoting the interaction between TAZ
and PP1 and that this function of ASPP2 requires the TAZ
WW domain.
It has been reported that a short peptide from ASPP2 con-
taining the PP1-binding motif (RVXF) interacts with the cata-
lytic subunit of PP1 (34). We then tested whether the ability
to interact with PP1A is required for ASPP2 to promote TAZ
dephosphorylation. As shown in Fig. 3F, WT ASPP2 overex-
pression dramatically decreased TAZ phosphorylation at Ser-
89, whereas the PP1-interacting defective RV mutant, in
which the arginine and valine in the RVXF motif were re-
placed by glutamate and aspartate, totally blocked this effect.
In contrast, ASPP2 (but not scrambled) RNAi interference
oligonucleotides significantly increased TAZ phosphorylation
at Ser-89 (Fig. 3G). These data support a role of endogenous
ankyrin repeat-containing, SH3 domain-containing, and pro-
line-rich region-containing protein 2 in promoting TAZ de-
phosphorylation and a potential mechanism by increasing the
interaction between TAZ and PP1A.
PP1A and ASPP2 Promote TAZNuclear Localization—
TAZ phosphorylation at Ser-89 creates a 14-3-3-binding site
that results in cytoplasmic retention. This suggests that TAZ
dephosphorylation by PP1A could affect its interaction with
14-3-3 and subcellular localization. To this end, we examined
the binding between TAZ and 14-3-3 with or without PP1A
coexpression. We observed that PP1A overexpression signifi-
cantly decreased the binding between TAZ and 14-3-3 (Fig.
4A). Consistently, phosphatase inhibitor calyculin A and oka-
daic acid treatment increased the interaction between TAZ
and 14-3-3 (Fig. 4B). We also observed that coexpression of
WT ASPP2 significantly decreased the interaction between
TAZ and 14-3-3. In contrast, the RV mutant was totally inac-
tive in affecting the binding between TAZ and 14-3-3 (Fig.
4C). Furthermore, PP1A overexpression resulted in a dra-
matic increase in TAZ nuclear localization, and ASPP2 had a
similar effect (Fig. 4D). Moreover, okadaic acid treatment led
to TAZ cytoplasmic retention (Fig. 4E). Collectively, our data
suggest that PP1A and ASPP2 promote TAZ nuclear localiza-
tion via dephosphorylation.
PP1A and ASPP2 Regulate TAZ Target Gene Expression—
TAZ is known to induce epithelial-mesenchymal transition
and promote cell proliferation (6, 12). As a transcription co-
activator, TAZ exerts its biological function by modulating
gene expression. To determine the functional significance of
PP1A and ASPP2 in TAZ regulation, we performed quantita-
tive PCR to examine the PP1A and ASPP2 effect on epithelial-
mesenchymal transition markers and cell growth markers,
which are regulated by TAZ. As shown in Fig. 5A, PP1A over-
expression significantly enhanced the ability of TAZ to induce
N-cadherin, a marker for mesenchymal cells, and to reduce
E-cadherin, a marker for epithelial cells, as determined in
MCF10A cells stably expressing TAZ and PP1A. Similarly,
coexpression of PP1A increased the TAZ-induced expression
of CTGF,3 which is a TAZ target gene involved in promoting
cell growth (Fig. 5A). Furthermore, ASPP2 knockdown signifi-
cantly decreased CTGF expression in MCF10A cells stably
expressing TAZ but had a much weaker effect in cells stably
expressing TAZ(4SA), which is a constitutively active mu-
tant no longer inhibited by phosphorylation (Fig. 5B). Col-
lectively, the above data support that PP1 and ankyrin re-
peat-containing, SH3 domain-containing, and proline-rich
region-containing protein 2 activate TAZ as indicated by
the increase of TAZ-dependent gene expression. More-
over, the effect of PP1 and ASPP2 on TAZ target gene ex-
pression appears to be mediated via TAZ
dephosphorylation.
DISCUSSION
In this work, we have shown that both PP1A and ASPP2
promote TAZ dephosphorylation, therefore resulting in TAZ
nuclear retention and induction of TAZ target gene expres-
sion. Our study reveals a molecular mechanism of dynamic
reversible phosphorylation in regulation of TAZ by the Hippo
pathway and PP1A.
We have previously demonstrated that phosphorylation
negatively regulates TAZ by two mechanisms. Phosphoryla-
tion of Ser-89 inhibits TAZ by cytoplasmic sequestration,
whereas phosphorylation of Ser-311 inactivates TAZ by pro-
moting ubiquitination and degradation (15). Therefore, phos-
phorylation plays a major role in TAZ regulation. In this
study, we have shown that TAZ phosphorylation is also con-
trolled by PP1A and its interacting protein ASPP2. Several
lines of evidence support a role of PP1A in TAZ dephosphor-
ylation. First, PP1A is identified in the TAZ complex, and the
interaction between TAZ and PP1A is confirmed by recipro-
cal co-immunoprecipitation. The PP1-interacting protein
ASPP2 is also consistently identified in the TAZ complex.
Second, coexpression of PP1A reduces the TAZ mobility shift
and decreases TAZ phosphorylation at Ser-89 and Ser-311, as
indicated by Western blotting with the anti-phospho-Ser-89
TAZ and anti-phospho-Ser-311 TAZ antibodies. Third, both
phosphatase inhibitors okadaic acid and calyculin A increase
TAZ phosphorylation at Ser-89 and Ser-311. The concentra-
tion of okadaic acid needed to increase TAZ phosphorylation
is consistent with PP1A being the target phosphatase. Fourth,
PP1 efficiently dephosphorylates both Ser-89 and Ser-311 in
TAZ by in vitro reactions. Furthermore, coexpression of
PP1A promotes TAZ nuclear localization and TAZ stabiliza-
tion. Interestingly, YAP dephosphorylation is not similarly
controlled by PP1A (supplemental Fig. 4). It is worth the ef-
fort to identify the phosphatase responsible for YAP
dephosphorylation.
Previously, ASPP2 was identified as a PP1-interacting
protein, but the biological function of this interaction re-
mained to be explored. Here, we have shown that ASPP2
3 The abbreviations used are: CTGF, connective tissue growth factor; -TrCP,
beta-transducin repeat containing protein.
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promotes TAZ-PP1 interaction by binding with both TAZ
and PP1 through different domains, thus enhancing dephos-
phorylation of TAZ. Interestingly, although the WW domain
mutant significantly abolishes the interaction between TAZ
and ASPP2, ASPP2 still enhances dephosphorylation of TAZ,
indicating another indirect effect on TAZ. One possibility is
that ASPP2 can regulate insulin receptor substrate 1 (35),
which has been found to bind with YAP in the cytoplasm (36),
to affect the YAP/TAZ subcellular location and phosphoryla-
tion level.
FIGURE 4. PP1A and ASPP2 promote TAZ nuclear localization. A, PP1A decreases the interaction between TAZ and 14-3-3. The plasmids were cotrans-
fected into 293T cells as indicated. FLAG-TAZ was immunoprecipitated (IP) with anti-FLAG antibody, and the co-precipitated Myc-14-3-3 was detected by
Myc Western blotting. B, phosphatase inhibitors increase the interaction between TAZ and 14-3-3. The plasmids were cotransfected into 293T cells as indi-
cated. FLAG-TAZ was immunoprecipitated with anti-FLAG antibody, and the co-precipitated HA-14-3-3 was detected by HA Western blotting. CA, calyculin
A. C, the PP1-binding motif RVXF is required for ASPP2 to inhibit the interaction between TAZ and 14-3-3. The plasmids were cotransfected into 293T cells
as indicated. FLAG-TAZ was immunoprecipitated with anti-FLAG antibody, and the co-precipitated HA-14-3-3 was detected by HA Western blotting.
D, PP1A and ASPP2 promote TAZ nuclear localization. The plasmids were cotransfected into 293T cells as indicated. Cytoplasmic (Cyto) and nuclear (Nuc)
fractions were separated for Western blot analysis as indicated. E, phosphatase inhibitor treatment increases the TAZ cytoplasmic sequester. BT549 cells
were treated with 100 nM okadaic acid (OA) for 2 h. Immunofluorescence was performed to determine TAZ cytoplasmic/nuclear distribution with anti-TAZ
antibody (BD Biosciences).
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ASPP2 is a haploinsufficient tumor suppressor (37), and it
promotes the apoptosis function of p53, similar to p63 and
p73 (22). Besides the p53 family, ASPP2 interacts with numer-
ous proteins, including YAP. However, the biological function
of the interaction between ankyrin repeat-containing, SH3
domain-containing, and proline-rich region-containing pro-
tein 2 and non-p53 families is largely unknown. The interac-
tion between ASPP2 and APP-BP1 inhibits apoptosis in
neuronal cells, indicating that ASPP2 could have an anti-ap-
optotic function (30). Here, we have shown that ASPP2 acti-
vates TAZ, also indicating an anti-apoptotic function because
TAZ inhibits apoptosis. These studies suggest that the biolog-
ical significance of ASPP2 in cooperating with non-p53 fami-
lies is cell context-dependent.
ASPP2 interacts with TAZ and PP1A via the PY motif and
RVXF motif, respectively. ASPP2 belongs to the ASPP family,
including pro-apoptotic ASPP1 and anti-apoptotic iASPP
(22–24). ASPP1, but not iASPP, also possesses a PY motif
and an RVXF motif, implying that ASPP1 may also regulate
the TAZ phosphorylation level in a manner similar to
ASPP2.
TAZ has also been implicated in human tumorigenesis.
TAZ is inhibited by the Hippo pathway, which contains the
well established human tumor suppressor NF2 (6) and WW45
and Mob, which are mutated in human cancer cell lines (38,
39). In addition, overexpression of TAZ in MCF10A cells can
promote cell proliferation, epithelial-mesenchymal transition,
and oncogenesis (6, 12, 20). We previously demonstrated that
LATS phosphorylates TAZ to promote its ubiquitin-mediated
degradation, leading to functional inhibition of TAZ (15). No-
tably, elevated TAZ expression is observed in 20% of breast
cancers, especially invasive ductal carcinomas (12). Here, we
demonstrated that PP1A coupled with ASPP2 antagonizes the
function of LATS to regulate the reversible phosphorylation
of TAZ. Given the potential role of TAZ in human cancer, it
would be interesting to examine the expression of PP1 and
ASPP2 in TAZ-overexpressed breast cancer tissues. Our stud-
ies shed light on the dynamic regulation of TAZ phosphoryla-
FIGURE 5. PP1A and ASPP2 promote TAZ target gene expression. A, PP1A increases N-cadherin and CTGF expression and decreases E-cadherin expres-
sion in pBABE-FLAG-TAZ/MCF10A cells. Total RNA was extracted from vector-expressing, pBABE-FLAG-TAZ/pQCXIH-vector-, and pBABE-FLAG-TAZ/pQCXIH-
PP1A-expressing MCF10A cells, and quantitative PCR was performed to determine E-cadherin, N-cadherin, and CTGF expression. All data are normalized to
GAPDH. B, ASPP2 knockdown decreases CTGF expression. ASPP2 was depleted in WT TAZ and TAZ(4SA)-expressing MCF10A cells using siRNA against hu-
man ASPP2 (siASPP2). The efficiency of ASPP2 knockdown and down-regulation of CTGF was determined by relative quantitative PCR.
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tion and potential mechanisms of TAZ activation in human
cancer.
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